Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

Monday, October 28, 2024, at 8:30 a.m. EDT

DUBLIN and CHICAGO, Oct. 28, 2024 /PRNewswire/ --

WHO:

Iterum Therapeutics plc (Nasdaq: ITRM) is focused on delivering
differentiated anti-infectives aimed at combatting the global crisis of multi-drug
resistant pathogens to significantly improve the lives of people affected by
serious and life-threatening diseases around the world.

Read more at prnewswire.com